BMS184394

BMS184394 is an experimental small molecule compound belonging to the class of naphthalenecarboxylic acids. It was developed as a selective inhibitor of retinoic acid receptor gamma (RARγ), with additional but weaker activity against retinoic acid receptor beta (RARβ) and minimal activity against retinoic acid receptor alpha (RARα). The compound has been studied primarily in preclinical settings for its potential to modulate gene expression regulated by retinoic acid receptors. Its mechanism involves direct binding and inhibition of RARγ. BMS184394 was developed by Bristol Myers Squibb as a research tool and potential therapeutic agent; however, it has not advanced into clinical development or received regulatory approval[1][4][9].

Other names

6-[(S)-hydroxy-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)methyl]naphthalene-2-carboxylic acid